Schonfeld Strategic Advisors’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-20,000
| Closed | -$478K | – | 2545 |
|
|
2021
Q1 | $478K | Sell |
20,000
-141,955
| -88% | -$2.64M | 0.01% | 1161 |
|
|
2020
Q4 | $2.37M | Sell |
161,955
-28,668
| -15% | -$380K | 0.03% | 561 |
|
|
2020
Q3 | $2.71M | Buy |
190,623
+79,794
| +72% | +$1.22M | 0.05% | 425 |
|
|
2020
Q2 | $1.63M | Buy |
+110,829
| New | +$1.13M | 0.04% | 465 |
|
|
2020
Q1 | – | Sell |
-83,900
| Closed | -$403K | – | 1674 |
|
|
2019
Q4 | $403K | Buy |
83,900
+61,400
| +273% | +$339K | 0.01% | 839 |
|
|
2019
Q3 | $137K | Buy |
+22,500
| New | +$140K | ﹤0.01% | 936 |
|
|
2019
Q2 | – | Sell |
-167,400
| Closed | -$1.19M | – | 1352 |
|
|
2019
Q1 | $1.19M | Buy |
167,400
+17,400
| +12% | +$115K | 0.04% | 459 |
|
|
2018
Q4 | $729K | Sell |
150,000
-226,000
| -60% | -$1.18M | 0.03% | 551 |
|
|
2018
Q3 | $2.76M | Buy |
376,000
+99,300
| +36% | +$729K | 0.12% | 228 |
|
|
2018
Q2 | $1.77M | Sell |
276,700
-23,300
| -8% | -$154K | 0.1% | 290 |
|
|
2018
Q1 | $1.63M | Buy |
300,000
+150,000
| +100% | +$746K | 0.12% | 232 |
|
|
2017
Q4 | $626K | Sell |
150,000
-60,000
| -29% | -$361K | 0.05% | 407 |
|
|
2017
Q3 | $2.02M | Sell |
210,000
-201,600
| -49% | -$2.09M | 0.18% | 156 |
|
|
2017
Q2 | $4.87M | Buy |
411,600
+86,600
| +27% | +$1.11M | 0.5% | 40 |
|
|
2017
Q1 | $4.17M | Buy |
+325,000
| New | +$3.91M | 0.42% | 62 |
|
Schonfeld Strategic Advisors's GNMK Position: Q2 2021 in Review
Schonfeld Strategic Advisors sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 20,000 shares — an estimated $478K sold.
Schonfeld Strategic Advisors first reported a position in GNMK in Q1 2017 and held it in 15 quarters. The position peaked at $4.87M in Q2 2017. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Schonfeld Strategic Advisors reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 20,000 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $478K.
- Schonfeld Strategic Advisors first reported a position in GenMark Diagnostics, Inc in Q1 2017 and held it in 15 quarters.
- Schonfeld Strategic Advisors's GenMark Diagnostics, Inc position peaked at $4.87M in Q2 2017.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.